MAINZ, Germany, August 7, 2023 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today reported financial results for the three and six months ended June 30, 2023, and provided an update on its corporate progress.
“We are progressing our oncology pipeline into late-stage development, having launched a pivotal Phase 3 trial and preparing for additional trials with registrational potential in the coming months,” said Prof. Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. “Simultaneously, we are enhancing our infectious disease pipeline to address global health needs and are developing an Omicron XBB.1.5-adapted monovalent COVID-19 vaccine to become available for the upcoming fall-winter season, subject to regulatory approvals.”
Financial Review for the Second Quarter and First Half of 2023
in millions €, except per share data | Second Quarter 2023 | Second Quarter 2022 | First Half 2023 | First Half 2022 |
Total Revenues2 | 167.7 | 3,196.5 | 1,444.7 | 9,571.1 |
Net Profit / (Loss) | (190.4) | 1,672.0 | 311.8 | 5,370.8 |
Diluted Earnings / (Loss) per Share | (0.79) | 6.45 | 1.28 | 20.69 |
Total revenues reported were €167.7 million2 for the three months ended June 30, 2023, compared to €3,196.5 million for the comparative prior year period. For the six months ended June 30, 2023, total revenues were €1,444.7 million2, compared to €9,571.1 million for the comparative prior year period. Write-offs by BioNTech’s collaboration partner Pfizer, Inc. (“Pfizer”) significantly reduced the Company’s gross profit share in the second quarter and hence negatively influenced its revenues for the three months ended June 30, 2023.
Cost of sales were €162.9 million for the three months ended June 30, 2023, compared to €764.6 million for the comparative prior year period. For the six months ended June 30, 2023, cost of sales were €258.9 million, compared to €2,058.7 million for the comparative prior year period. The change was in line with decreasing COVID-19 vaccine sales.
Research and development expenses were €373.4 million for the three months ended June 30, 2023, compared to €399.6 million for the comparative prior year period. For the six months ended June 30, 2023, research and development expenses were €707.4 million, compared to €685.4 million for the comparative prior year period. Research and Development (R&D) expenses are mainly influenced by progressing clinical studies for pipeline candidates, the development of variant adapted as well as next generation COVID-19 vaccines and expanding R&D headcount.
General and administrative expenses were €122.7 million for the three months ended June 30, 2023, compared to €130.0 million for the comparative prior year period. For the six months ended June 30, 2023, general and administrative expenses were €242.1 million, compared to €220.8 million for the comparative prior year period. G&A expenses were mainly influenced by increased expenses for IT services as well as expanding the G&A headcount.
Income taxes were realized with an amount of €221.8 million tax income for the three months ended June 30, 2023, compared to €647.3 million of tax expenses accrued for the comparative prior year period. For the six months ended June 30, 2023, income taxes were realized with an amount of €16.3 million tax income, compared to €1,966.6 million tax expenses accrued for the comparative prior year period. The derived annual effective income tax rate for the six months ended June 30, 2023, was minus 5.5% which is expected to change over the 2023 financial year to be in line with the updated estimated annual cash effective income tax rate of somewhere around 21% for the BioNTech Group.
Net loss was €190.4 million for the three months ended June 30, 2023, compared to €1,672.0 million net profit for the comparative prior year period. For the six months ended June 30, 2023, net profit was €311.8 million, compared to €5,370.8 million net profit for the comparative prior year period.
Cash and cash equivalents as well as security investments were €14,166.6 million as well as €2,667.0 million, respectively, as of June 30, 2023. Subsequent to the end of the reporting period, the payment settling BioNTech’s gross profit share for the first quarter of 2023 (as defined by the contract with Pfizer) in the amount of €1,059.2 million was received from BioNTech's collaboration partner as of July 17, 2023. In addition, until early August 2023, €437.7 million was received in connection with the amended COVID-19 Vaccine Purchase Agreement with the European Commission (EC).
Loss per share was €0.79 for the three months ended June 30, 2023, compared to a diluted earnings per share €6.45 for the comparative prior year period. For the six months ended June 30, 2023, diluted earnings per share was €1.28, compared to €20.69 diluted earnings per share for the comparative prior year period.
Shares outstanding as of June 30, 2023, were 239,771,156, excluding 8,781,044 shares in treasury.
In March 2023, BioNTech initiated a new share repurchase program pursuant to which the Company may purchase American Depositary Shares, or ADSs, each representing one ordinary share of the Company, in the amount of up to $0.5 billion during the remainder of 2023. During the three months ended June 30, 2023, 1,532,685 American Depositary Shares were repurchased under the share repurchase program of ADSs at an average price of €100.45 ($108.923), for total consideration of €154.0 million ($166.9 million3).
Cash outflows and share consideration in connection with the acquisition of InstaDeep Ltd. (“InstaDeep”) on July 31, BioNTech invested approximately €450 million not including potential future milestones.
“We enter the second half of 2023 with a strong financial position, on track to launch our new variant-adapted COVID-19 vaccine and to conduct multiple clinical trials with registrational potential across our oncology and infectious disease pipeline. The COVID-19 vaccine market remains highly dynamic and difficult to fully predict. Along with our partner Pfizer, the Company continues to focus on supporting successful vaccinations during the autumn respiratory infection season,” said Jens Holstein, CFO of BioNTech. ”It is our goal to become a multi-product company by investing in our own clinical programs and by complementing them with additional compounds from our partners. With some uncertainty on the revenue line, we are also carefully watching our spending by revisiting our cost base while remaining focused on executing against our strategic goals and providing value to the public and our shareholders.”
Outlook for the 2023 Financial Year
The Company reiterates its COVID-19 vaccine revenue guidance and updates its previous expense and capex guidance for the 2023 financial year:
BioNTech COVID-19 Vaccine Revenues for the 2023 Financial Year:
Estimated BioNTech COVID-19 vaccine revenues for the full 2023 financial year | ~ €5 billion |
This estimate reflects expected revenues related to BioNTech’s share of gross profit from COVID-19 vaccine sales in the collaboration partners’ territories, from direct COVID-19 vaccine sales to customers in BioNTech’s territory and expected revenues generated from products manufactured by BioNTech and sold to collaboration partners, which may be influenced by costs such as inventory write-offs once materialized and shared with the collaboration partner Pfizer.
Revenue guidance is based on various assumptions, including, but not limited to, the expected transition from an advanced purchase agreement environment to commercial market ordering starting in some geographies and an expected regulatory recommendation to adapt the COVID-19 vaccines to address newly circulating variants or sublineages of SARS-CoV-2. While vaccine adaptation is expected to lead to increased demand, fewer primary vaccinations and lowered population-wide levels of boosting are anticipated. In addition, seasonal demand is assumed, moving expected revenue generation to the second half of the year 2023 as previously reported. The revenues guidance reflects the revenues as specified by the amendment of the contractual agreement with the EC on behalf of the member states while it largely remains dependent on revenues generated in BioNTech’s collaboration partner’s territories. The market dynamics for COVID-19 vaccines are influenced by various factors which underlie substantial uncertainties and might affect the demand for COVID-19 vaccines in general as well as the Company’s estimated revenues.
Planned 2023 Financial Year Expenses and Capex4:
Previous Guidance | Updated Guidance | |
R&D expenses5 | €2,400m - €2,600m | €2,000m - €2,200m |
SG&A expenses | €650m - €700m | €600m - €700m |
Capital expenditures for operating activities6 | €500m - €600m | €350m - €450m |
Estimated 2023 Financial Year Tax Assumptions:
Previous Guidance | Updated Guidance | |
BioNTech Group estimated annual cash effective income tax rate7 | ~ 27% | ~ 21% |
The full interim unaudited condensed consolidated financial statements can be found in BioNTech’s Report on Form 6-K, filed today with the United States Securities and Exchange Commission (“SEC”) and available at https://www.sec.gov/.
Endnotes
1 Financial information is prepared and presented in Euros and numbers are rounded to millions and billions of Euros in accordance with standard commercial practice.
2 BioNTech’s profit share is estimated based on preliminary data shared between Pfizer and BioNTech as further described in the Annual Report. Any changes in the estimated share of the collaboration partner’s gross profit will be recognized prospectively.
3 Calculated applying the average foreign exchange rate for the three and six months ended June 30, 2023, as published by the German Central Bank (Deutsche Bundesbank).
4 Numbers reflect current base case projections and are calculated based on constant currency rates.
5 Numbers include effects identified from additional collaborations or potential M&A transactions to the extent disclosed and will be updated as needed.
6 Numbers exclude potential effects caused by or driven from collaborations or M&A transactions.
7 Numbers exclude potential effects caused by or driven from share-based payment settlements in the course of 2023.
Operational Review and Pipeline Update for the Second Quarter 2023 and Key Post Period-End Events
COVID-19 Marketed Products
Oncology Pipeline Highlights - Recent and upcoming trial starts and data readouts
BNT316/ONC-392 (gotistobart) is a next-generation anti-CTLA-4 monoclonal antibody candidate jointly developed by BioNTech and OncoC4, Inc. (“OncoC4”). BNT316/ONC-392 offers a potentially differentiated safety profile that may allow for higher dosing and longer duration of treatment both as a monotherapy and in combination with other therapies.
BNT323/DB-1303 is a HER2-targeted antibody-drug conjugate (ADC) candidate, being developed in collaboration with Duality Biologics (Suzhou) Co. Ltd. (“DualityBio”).
BNT324/DB-1311 is a topoisomerase-1 inhibitor-based ADC candidate being developed in collaboration with DualityBio.
BNT116 is based on BioNTech’s FixVac platform, a wholly owned, systemically administered, off-the-shelf mRNA-based cancer vaccine candidate. This candidate is being evaluated for the treatment of advanced NSCLC.
BNT122 (Autogene cevumeran) is an mRNA cancer vaccine candidate based on an individualized neoantigen-specific immunotherapy (iNeST) approach being developed in collaboration with Genentech, a member of the Roche Group (”Roche”).
BNT211 is an autologous Claudin-6 (CLDN6)-targeting chimeric antigen receptor (CAR) T cell therapy candidate that is being tested alone and in combination with an investigational CAR-T cell Amplifying RNA Vaccine compound, or CARVac, encoding CLDN6.
Corporate Update for the Second Quarter 2023 and Key Post Period-End Events
Environmental, Social, and Governance (ESG)
BioNTech was founded out of a responsibility to patients and to society and this is still the vision that drives the Company. It gives grounds for BioNTech’s enhanced responsibility: for translating the Company’s science into the health of people worldwide and democratizing access to innovative medicines, for environmental and climate protection, for respecting human rights and for fostering the full potential of all employees.
In March 2023, BioNTech published its third ESG report (Sustainability Report 2022). The report highlights the Company’s progress in developing novel medicines and introducing scalable technological innovations. It describes BioNTech’s science-based climate goals (under SBTi review), actions and climate risk management as well as the status of the Companies’ human rights strategy and due diligence. The report addresses diversity, inclusion, equity and belonging, and highlights the importance of BioNTech’s values and culture.
BioNTech recognizes its responsibility as a corporate citizen and is committed to supporting its local communities and beyond through donations, sponsorships and volunteer activities.
Upcoming Investor and Analyst Events
Conference Call and Webcast Information
BioNTech invites investors and the general public to join a conference call and webcast with investment analysts today, August 7, 2023, at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the second quarter of 2023.
To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a pin number will be provided.
The slide presentation and audio of the webcast will be available via this link.
Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page of the Investor Relations section of the Company’s website at https://biontech.com. A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company’s website for 30 days following the call.
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bispecific immune checkpoint modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including DualityBio, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, OncoC4, Regeneron, Sanofi, and Pfizer.
For more information, please visit www.BioNTech.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech's expected revenues and net profit related to sales of BioNTech's COVID-19 vaccine, referred to as COMIRNATY where approved for use under full or conditional marketing authorization, in territories controlled by BioNTech's collaboration partners, particularly for those figures that are derived from preliminary estimates provided by BioNTech's partners; the rate and degree of market acceptance of BioNTech's COVID-19 vaccine and, if approved, BioNTech's investigational medicines; expectations regarding anticipated changes in COVID-19 vaccine demand, including changes to the ordering environment and expected regulatory recommendations to adapt vaccines to address new variants or sublineages; the initiation, timing, progress, results, and cost of BioNTech's research and development programs, including those relating to additional formulations of BioNTech's COVID-19 vaccine, and BioNTech's current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work and the availability of results; our expectations with respect to our intellectual property; the impact of the Company’s acquisition of InstaDeep Ltd. and collaboration and licensing agreements with OncoC4, Inc., Duality Biologics (Suzhou) Co. Ltd. and others; the development of sustainable vaccine production and supply solutions, and the nature and feasibility of these solutions; and BioNTech's estimates of commercial and other revenues, cost of sales, research and development expenses, sales and marketing expenses, general and administrative expenses, capital expenditures, income taxes, net profit, cash, cash equivalents and security investments, shares outstanding and cash outflows and share consideration. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: BioNTech's pricing and coverage negotiations with governmental authorities, private health insurers and other third-party payors after BioNTech's initial sales to national governments; the future commercial demand and medical need for initial or booster doses of a COVID-19 vaccine; competition from other COVID-19 vaccines or related to BioNTech's other product candidates, including those with different mechanisms of action and different manufacturing and distribution constraints, on the basis of, among other things, efficacy, cost, convenience of storage and distribution, breadth of approved use, side-effect profile and durability of immune response; the timing of and BioNTech's ability to obtain and maintain regulatory approval for BioNTech's product candidates; the ability of BioNTech’s COVID-19 vaccines to prevent COVID-19 caused by emerging virus variants; BioNTech's and its counterparties’ ability to manage and source necessary energy resources; BioNTech's ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech's third-party collaborators to continue research and development activities relating to BioNTech's development candidates and investigational medicines; the impact of the COVID-19 pandemic on BioNTech's development programs, supply chain, collaborators and financial performance; unforeseen safety issues and potential claims that are alleged to arise from the use of BioNTech's COVID-19 vaccine and other products and product candidates developed or manufactured by BioNTech; BioNTech's and its collaborators’ ability to commercialize and market BioNTech's COVID-19 vaccine and, if approved, its product candidates; BioNTech's ability to manage its development and expansion; regulatory developments in the United States and other countries; BioNTech's ability to effectively scale BioNTech's production capabilities and manufacture BioNTech's products, including BioNTech's target COVID-19 vaccine production levels, and BioNTech's product candidates; risks relating to the global financial system and markets; and other factors not known to BioNTech at this time. You should review the risks and uncertainties described under the heading “Risk Factors” in BioNTech's Report on Form 6-K for the period ended June 30, 2023 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on BioNTech’s current expectations and speak only as of the date hereof.
Contacts
Investor Relations
Victoria Meissner, M.D.
+1 617 528 8293
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
This email address is being protected from spambots. You need JavaScript enabled to view it.
Interim Consolidated Statements of Profit or Loss
Three months ended June 30, | Six months ended June 30, | |||
2023 | 2022 | 2023 | 2022 | |
(in millions €, except per share data) | (unaudited) | (unaudited) | (unaudited) | (unaudited) |
Revenues | ||||
Commercial revenues | 166.4 | 3,166.3 | 1,442.9 | 9,528.5 |
Research & development revenues | 1.3 | 30.2 | 1.8 | 42.6 |
Total revenues | 167.7 | 3,196.5 | 1,444.7 | 9,571.1 |
Cost of sales | (162.9) | (764.6) | (258.9) | (2,058.7) |
Research and development expenses | (373.4) | (399.6) | (707.4) | (685.4) |
Sales and marketing expenses | (18.1) | (17.8) | (30.3) | (32.1) |
General and administrative expenses | (122.7) | (130.0) | (242.1) | (220.8) |
Other operating expenses | (74.2) | (240.7) | (192.3) | (309.5) |
Other operating income | 20.3 | 565.8 | 77.4 | 697.7 |
Operating income / (loss) | (563.3) | 2,209.6 | 91.1 | 6,962.3 |
Finance income | 152.4 | 115.5 | 208.9 | 387.6 |
Finance expenses | (1.3) | (5.8) | (4.5) | (12.5) |
Profit / (loss) before tax | (412.2) | 2,319.3 | 295.5 | 7,337.4 |
Income taxes | 221.8 | (647.3) | 16.3 | (1,966.6) |
Profit / (Loss) for the period | (190.4) | 1,672.0 | 311.8 | 5,370.8 |
Earnings per share | ||||
Basic profit / (loss) for the period per share | (0.79) | 6.86 | 1.29 | 22.00 |
Diluted profit / (loss) for the period per share | (0.79) | 6.45 | 1.28 | 20.69 |
Interim Consolidated Statements of Financial Position
June 30, | December 31, | ||
(in millions €) | 2023 | 2022 | |
Assets | (unaudited) | ||
Non-current assets | |||
Intangible assets | 501.4 | 219.7 | |
Property, plant and equipment | 691.1 | 609.2 | |
Right-of-use assets | 202.9 | 211.9 | |
Other financial assets | 1,374.3 | 80.2 | |
Other non-financial assets | 2.5 | 6.5 | |
Deferred tax assets | 239.5 | 229.6 | |
Total non-current assets | 3,011.7 | 1,357.1 | |
Current assets | |||
Inventories | 448.9 | 439.6 | |
Trade and other receivables | 2,657.9 | 7,145.6 | |
Contract assets | 5.9 | — | |
Other financial assets | 1,390.7 | 189.4 | |
Other non-financial assets | 212.3 | 271.9 | |
Income tax assets | 331.6 | 0.4 | |
Cash and cash equivalents | 14,166.6 | 13,875.1 | |
Total current assets | 19,213.9 | 21,922.0 | |
Total assets | 22,225.6 | 23,279.1 | |
Equity and liabilities | |||
Equity | |||
Share capital | 248.6 | 248.6 | |
Capital reserve | 1,424.4 | 1,828.2 | |
Treasury shares | (8.8) | (5.3) | |
Retained earnings | 19,144.8 | 18,833.0 | |
Other reserves | (902.5) | (848.9) | |
Total equity | 19,906.5 | 20,055.6 | |
Non-current liabilities | |||
Lease liabilities, loans and borrowings | 167.1 | 176.2 | |
Other financial liabilities | 6.1 | 6.1 | |
Income tax liabilities | — | 10.4 | |
Provisions | 8.6 | 8.6 | |
Contract liabilities | 302.1 | 48.4 | |
Other non-financial liabilities | 11.7 | 17.0 | |
Deferred tax liabilities | 4.5 | 6.2 | |
Total non-current liabilities | 500.1 | 272.9 | |
Current liabilities | |||
Lease liabilities, loans and borrowings | 38.6 | 36.0 | |
Trade payables and other payables | 228.6 | 204.1 | |
Other financial liabilities | 172.5 | 785.1 | |
Refund liabilities | — | 24.4 | |
Income tax liabilities | 554.9 | 595.9 | |
Provisions | 374.8 | 367.2 | |
Contract liabilities | 201.2 | 77.1 | |
Other non-financial liabilities | 248.4 | 860.8 | |
Total current liabilities | 1,819.0 | 2,950.6 | |
Total liabilities | 2,319.1 | 3,223.5 | |
Total equity and liabilities | 22,225.6 | 23,279.1 |
Interim Consolidated Statements of Cash Flows
Three months ended June 30, | Six months ended June 30, | ||||
2023 | 2022 | 2023 | 2022 | ||
(in millions €) | (unaudited) | (unaudited) | (unaudited) | (unaudited) | |
Operating activities | |||||
Profit / (Loss) for the period | (190.4) | 1,672.0 | 311.8 | 5,370.8 | |
Income taxes | (221.8) | 647.3 | (16.3) | 1,966.6 | |
Profit / (Loss) before tax | (412.2) | 2,319.3 | 295.5 | 7,337.4 | |
Adjustments to reconcile profit before tax to net cash flows: | |||||
Depreciation and amortization of property, plant, equipment, intangible assets and right-of-use assets | 31.9 | 33.2 | 63.3 | 60.8 | |
Share-based payment expenses | 13.1 | 14.8 | 21.7 | 25.0 | |
Net foreign exchange differences | (397.0) | (344.6) | (343.9) | (338.5) | |
Loss on disposal of property, plant and equipment | 0.1 | 0.2 | 0.3 | 0.2 | |
Finance income excluding foreign exchange differences | (126.6) | (1.5) | (208.9) | (218.8) | |
Finance expense excluding foreign exchange differences | 1.3 | 5.8 | 2.5 | 12.5 | |
Movements in government grants | — | — | (3.0) | — | |
Net loss on derivative instruments at fair value through profit or loss | 12.0 | 86.5 | 88.2 | 84.6 | |
Working capital adjustments: | |||||
Decrease in trade and other receivables, contract assets and other assets | 5,123.6 | 3,174.8 | 6,017.4 | 2,771.3 | |
Decrease / (increase) in inventories | (24.8) | 91.6 | (9.3) | 134.8 | |
(Decrease) / increase in trade payables, other financial liabilities, other liabilities, contract liabilities, refund liabilities and provisions | 592.7 | (663.1) | (268.9) | 194.4 | |
Interest received | 42.5 | 1.5 | 96.1 | 2.2 | |
Interest paid | (1.3) | (5.8) | (2.5) | (12.2) | |
Income tax paid | (437.3) | (791.4) | (1,282.2) | (2,081.4) | |
Share-based payments | (31.3) | (2.2) | (757.0) | (3.0) | |
Net cash flows from operating activities | 4,386.7 | 3,919.1 | 3,709.3 | 7,969.3 | |
Investing activities | |||||
Purchase of property, plant and equipment | (67.2) | (70.6) | (112.4) | (114.7) | |
Purchase of intangible assets and right-of-use assets | (242.1) | (4.8) | (251.7) | (21.5) | |
Investment in other financial assets | (1,982.5) | (3.0) | (2,663.1) | (30.0) | |
Proceeds from maturity of other financial assets | — | — | — | 375.2 | |
Net cash flows from / (used in) investing activities | (2,291.8) | (78.4) | (3,027.2) | 209.0 | |
Financing activities | |||||
Proceeds from issuance of share capital and treasury shares, net of costs | — | — | — | 110.5 | |
Proceeds from loans and borrowings | — | 0.2 | — | 0.2 | |
Repayment of loans and borrowings | — | — | — | (18.8) | |
Payments related to lease liabilities | (9.4) | (10.5) | (18.7) | (21.9) | |
Share repurchase program | (154.0) | (286.9) | (436.0) | (286.9) | |
Dividends | — | (484.3) | — | (484.3) | |
Net cash flows used in financing activities | (163.4) | (781.5) | (454.7) | (701.2) | |
Net increase in cash and cash equivalents | 1,931.5 | 3,059.2 | 227.4 | 7,477.1 | |
Change in cash and cash equivalents resulting from exchange rate differences | 91.2 | 111.5 | 64.1 | 165.0 | |
Cash and cash equivalents at the beginning of the period | 12,143.9 | 6,164.1 | 13,875.1 | 1,692.7 | |
Cash and cash equivalents as of June 30 | 14,166.6 | 9,334.8 | 14,166.6 | 9,334.8 |
Last Trade: | US$89.94 |
Daily Change: | -0.21 -0.23 |
Daily Volume: | 628,311 |
Market Cap: | US$21.390B |
September 05, 2024 July 30, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB